PLUS THERAPEUTICS INC (PSTV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.10+2.65%
Close 2026-08-27 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PSTV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -63.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
PSTV — debt issuance
Dated 2026-06-05
Entry into a Material Definitive Agreement. On June 1, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Distribution Agreement”) with Canaccord Genuity LLC (the “Agent”), pursuant to which the Company may issue and sell, from time to time (the “Offering”), shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $17,350,000 (the “Shares”), depending on market demand, with the Agent…
Why it matters: Helpful FDA feedback can help develop REYOBIQ. It can also affect future trial plans.
Watch forPositive feedback from FDA on the pivotal trial framework for REYOBIQ.
Also watch forBad feedback or no reply from the FDA about the main trial plan.
Why it matters: Updates on REYOBIQ's trial readiness show progress in a key treatment area.
Supportive ifConfirmation of pivotal trial framework for REYOBIQ by the end of Q3 2026.
Worry ifNo updates on pivotal trial framework or delays in trial readiness by the end of Q3 2026.
Why it matters: This role is key for advancing drug development and strategy. A strong leader can improve project outcomes.
Supportive ifA new Chief Development Officer has been announced. They have relevant experience.
Worry ifNo appointment is made within the next six months.
Why it matters: Earnings results will show how well the company is doing with money and operations.
Watch forQ2 revenue exceeds $1.5 million, indicating growth in CNSide and REYOBIQ.
Also watch forQ2 revenue is under $1 million. This shows ongoing financial problems.
Why it matters: Revenue growth is key to assessing the success of CNSide and REYOBIQ initiatives.
Supportive ifQ2 2026 revenue was over $1.0 million, showing growth from Q1.
Worry ifQ2 2026 revenue reported below $1.0 million, showing a decline.
Why it matters: Reaching this goal will show that CNSide diagnostics are selling well and in demand.
Supportive ifAnnualized test orders exceed 1,250 by the end of 2026.
Worry ifAnnualized test orders remain below 1,250 by the end of 2026.
Why it matters: A successful reverse stock split can improve share price and market perception. It may attract more investors.
Supportive ifThe reverse stock split is done. Shares are now stable above $1.
Worry ifThe stock price remains below $1 after the split.
Why it matters: A successful reverse stock split could help improve share price and attract investors.
Supportive ifA formal announcement detailing the terms and timing of the Reverse Stock Split.
Worry ifThe company decides against the Reverse Stock Split or delays the process.
Why it matters: Completing enrollment is key for the timeline to data readout in Q1 2027. This data is crucial for FDA discussions.
Supportive ifEnrollment in the ReSPECT-GBM trial is completed by the end of 2026.
Worry ifEnrollment is not completed by the end of 2026.
Why it matters: First dosing will signal progress in pediatric brain cancer treatment and validate the trial setup.
Supportive ifFirst dosing in the ReSPECT-PBC trial occurs in Q3 2026.
Worry ifFirst dosing does not occur in Q3 2026.
Why it matters: More payer coverage helps increase revenue. It also improves market access for CNSide diagnostics.
Supportive ifCNSide payer coverage exceeds 150 million lives by the end of 2026.
Worry ifCNSide payer coverage remains below 150 million lives by the end of 2026.
Why it matters: The data readout will show how well REYOBIQ works for glioblastoma.
Watch forPositive data readout from the ReSPECT-GBM trial in Q1 2027.
Also watch forNegative data readout from the ReSPECT-GBM trial in Q1 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$320 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $944 loss on $10,000 · 9.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,687 loss on $10,000 · 86.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.